BiologicalDrug
MEDI-6469 clinical trials
Also written MEDI6469.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
- MEDI6469
- 4
Studies by the year they started
5 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 4
Providence Health & Services (4) · MedImmune LLC (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (1) · Tremelimumab (1) · Durvalumab (1) · Rituximab (1)
Studies
Open first, then newest update. How each study uses MEDI-6469 is read from its arms, and is right about nine times in ten.
Testing it · 5
- Anti-OX40 Antibody in Head and Neck Cancer PatientsCompletedPhase 1Providence Health & ServicesNCT02274155Written as Anti-OX40 antibody administration
- Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal CancerTerminatedPhase 1Providence Health & ServicesNCT02559024Written as MEDI6469
- Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic LesionsCompletedPhase 1Providence Health & ServicesNCT01862900Written as MEDI6469
- Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate CancerCompletedPhase 1Providence Health & ServicesNCT01303705Written as Anti-OX40
- A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal AntibodiesTerminatedPhase 1/2MedImmune LLCNCT02205333Written as MEDI6469 Monotherapy
Codes
What other systems call MEDI-6469 · ClinicalTrials.gg INT016013
- UNII (FDA) AKV2GM43DDMEDI-6469One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AKV2GM43DD | MEDI-6469 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.